Review Article
Antibiotic-Impregnated Bone Grafts in Orthopaedic and Trauma Surgery: A Systematic Review of the Literature
Table 1
Literature review about antibiotic-impregnated bone grafts with specific attention on types of bone graft, antibiotics, and impregnation details.
| Study | Publication year | In vitro/animal/in vivo | Bone graft | Antibiotic(s) | Antibiotic/bone graft ratio | Impregnation method | Duration of antibiotic impregnation |
| Allende et al. [8] | 2010 | In vivo | Cancellous/ corticocancellous | Vancomycin | 1.5 g/case | n.r. | n.r. |
Borkhuu et al. [9] | 2008 | In vivo | Corticocancellous | Gentamicin | 8–10 mg/kg patient/30–60 cc | Solution | n.r. | Buttaro et al. [10] | 2003 | Animal | Cancellous | Vancomycin | 20 mg/6 g | Manual mixing | 15 min | Buttaro et al. [11] | 2005 | In vivo | Cancellous | Vancomycin | 1 g/femoral head | Manual mixing | 15 min | Buttaro et al. [12] | 2005 | In vivo | Cancellous | Vancomycin | 0.5 g/femoral head | Manual mixing | 15 min | Buttaro et al. [13] | 2005 | In vivo | Cancellous | Vancomycin | 1 g/femoral head | Manual mixing | 15 min | Chan et al. [14] | 1998 | In vivo | Cancellous | Vancomycin piperacillin | n.r. | Manual mixing | n.r. | Chan et al. [15] | 2000 | In vivo | Cancellous | Vancomycin piperacillin | n.r. | Manual mixing | n.r. | Chen et al. [16] | 2005 | In vivo | Cancellous | Vancomycin | 0.5 g/16 g | Manual mixing | n.r. | Day et al. [17] | 2005 | In vitro | Cortical | Gentamicin flucloxacillin | 1% solution of each antibiotic/graft | Iontophoresis | 1/5/10 min | English et al. [18] | 2002 | In vivo | Cancellous | Gentamicin vancomycin flucloxacillin | n.r. | n.r. | n.r. | Gray and Elves [19] |
1981 |
Animal | Corticocancellous | Benzylpenicillin streptomycin | 800,000 units/L/n.r. | Solution | n.r. | 500 mg/L/n.r. | | | Kanellakopoulou et al. [20] | 2008 | In vitro | Cancellous | Fusidic acid teicoplanin | 100 mg/mL | Solution | 60 min | Kanellakopoulou et al. [21] | 2010 | In vitro | Cancellous | Moxifloxacin | 500 mg/1 g | Solution | n.r. | Ketonis et al. [22] | 2010 | In vitro | Corticocancellous | Vancomycin | 10 mg/mL | Solution | 12–16 h | Ketonis et al. [23] | 2010 | In vitro | Cortical morselized | Vancomycin | 10 mg/mL | Solution | n.r. | Khoo et al. [24] | 2006 | In vivo | Segmental allograft | Gentamicin flucloxacillin | 1% gentamicin solution/graft 4% flucloxacillin solution/graft | Iontophoresis | 20 min | Lindsey et al. [25] | 1993 | Animal | Cancellous | Tobramycin | 90 mg/3 g | Manual mixing | n.r. | | | | | | 0.5 μg/10 μL | | | | | | | | 2.5 μg/10 μL | | | | | | | Cefazolin | 10 μg/10 μL | | | | | | | | 60 μg/10 μL | | |
Mathijssen et al. [26] | 2010 | In vitro | Cancellous | | 100 μg/10 μL | Solution | n.r. | | | | | | 0.5 μg/10 μL | | | | | | | | 2.5 μg/10 μL | | | | | | | Vancomycin | 10 μg/10 μL | | | | | | | | 70 μg/10 μL | | | | | | | | 100 μg/10 μL | | | McLaren [7] | 1989 | In vivo | Cancellous | Vancomycin tobramycin | 1 g/>20 g 720 mg/>20 g | Manual mixing | n.r. | Michalak et al. [27] | 2006 | In vivo | Segmental allograft | Gentamicin flucloxacillin | 1% gentamicin solution/graft 4% flucloxacillin solution/graft | Iontophoresis | 20 min | Miclau et al. [28] | 1993 | In vitro | Cancellous | Tobramycin | 25 mg/g | Manual mixing | n.r. | Petri [29] | 1984 | Animal | Bone-gelatin powder | Cephalothin tobramycin | 100–200 μg/mL b-g powder 1-2 mg/mL b-g-powder | Manual mixing | n.r. | Petri and Schaberg [30] | 1984 | Animal | Bone-gelatin powder | Cephalothin tobramycin | 200 μg/mL b-g powder 2 mg/mL b-g powder | Manual mixing | n.r. | Petri [31] | 1991 | Animal | Bone-gelatin powder | Cephalothin tobramycin | 1 mg/mL b-g powder 1 mg/mL b-g powder | Manual mixing | n.r. | Rhyu et al. [32] | 2003 | In vitro | Cancellous | Vancomycin | 125 mg/mL/66–70 mg | Solution | 24 h | Seber et al. [33] | 1998 | In vivo | Xenograft | Gentamicin | 25 mg/125 cc | Solution | 8 h | Winkler et al. [34] | 2000 | In vitro | Cancellous cortical | Vancomycin tobramycin | 100 mg/mL/block 80 mg/mL/block | Solution | 24 h | Winkler et al. [35] | 2006 | In vivo | Cancellous | Vancomycin tobramycin | 100 mg/cc 75 mg/cc | Solution | 24 h | Winkler et al. [36] | 2008 | In vivo | Cancellous | Vancomycin tobramycin | 100 mg/cc 75 mg/cc | Solution | 24 h | Witsø et al. [37] | 1999 | In vitro | Cancellous | Benzylpenicillin dicloxacillin cephalothin netilmicin vancomycin clindamycin ciprofloxacin rifampicin | 100 mg/mL/g 100 mg/mL/g 100 mg/mL/g 100 mg/mL/g 50 mg/mL/g 150 mg/mL/g 2 mg/mL/g 60 mg/mL/g | Solution | 10 min |
Witsø et al. [38] | 2000 | In vitro/animal | Cancellous | Benzylpenicillin cephalothin clindamycin netilmicin vancomycin ciprofloxacin rifampicin | 100 mg/mL/g 100 mg/mL/g 150 mg/mL/g 100 mg/mL/g 50 mg/mL/g 2 mg/mL/g 60 mg/mL/g | Solution | 10 min |
Witsø et al. [39] | 2002 | In vitro/animal | Cancellous | Netilmicin vancomycin | 100 mg/mL/g 100 mg/mL/g | Solution | 10 min |
Witsø et al. [40] | 2004 | In vivo | Cancellous | Netilmicin | 50/100 mg/mL/50 g | Solution | 10 min |
Witsø et al. [41] | 2005 | In vitro | Cortical | Netilmicin vancomycin ciprofloxacin rifampicin | 400 mg/mL/1.46 g 100 mg/mL/1.46 g 2 mg/mL/1.46 g 50 mg/mL/1.46 g | Solution | 1/10/100 h |
|
|
n.r.: not reported.
|